2024-10-31 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis:

**1. Performance vs. S&P 500:**

Thermo Fisher Scientific Inc. (TMO) is a leading provider of scientific instruments, consumables, and services. It has significantly outperformed the S&P 500 (VOO) over the analyzed period. 

* **TMO Cumulative Return:** 212.99%
* **VOO Cumulative Return:** 136.74%
* **Outperformance:** 76.25% 
* **Relative Outperformance Rank:** 35.79% (This means TMO's outperformance is in the 35.79th percentile of its historical range).

**2. Recent Price Action:**

* **Last Close:** 547.77
* **5-Day Moving Average:** 557.71
* **20-Day Moving Average:** 588.18
* **60-Day Moving Average:** 602.36

The price is currently below all three moving averages, indicating potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 21.96 (Oversold)
* **PPO:** -0.93 (Bearish)
* **Delta_Previous_Relative_Divergence:** -18.98 (Short-term Downward Trend)
* **Expected Return:** 46.87% (Potential for long-term outperformance over S&P 500)

The technical indicators suggest a potentially oversold situation with bearish momentum.  However, the expected return suggests strong long-term potential.

**4. Recent Earnings Performance:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2023-08-04 | 3.53 | 10.69 B$ |
| 2023-05-05 | 3.53 | 10.69 B$ |

The latest earnings announcement (2024-08-02) showed a strong performance with EPS exceeding analysts' expectations. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |
| 2023-06-30 | $10.69B | 39.78% |

TMO has consistently shown strong revenue growth and profitability, with a consistently high profit margin.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |
| 2023-06-30 | $43.75B | 3.11% |

TMO demonstrates a solid capital structure with a healthy return on equity.

**6. News and Recent Issues:**

**Recent Earnings Release:**

* TMO exceeded analyst expectations for both earnings and revenue in the most recent quarter.
* The company's focus on innovation and expansion into new markets were highlighted as key drivers of growth.

**Recent Market Outlook:**

* Several analysts have recently maintained "Buy" ratings on TMO.
* The company's strong track record of profitability and growth potential make it a favored pick among investors. 

**Analyst Opinions and Performance Highlights:**

* FINBOLD analysts highlight TMO's leadership position in the scientific instrumentation market and its ability to capitalize on industry trends. 
* The stock has consistently outperformed the market and is considered a strong long-term investment.

**7. Overall Analysis:**

TMO presents a compelling investment opportunity. Despite recent price dips, the company demonstrates a robust track record of growth, high profitability, and a strong financial position. While technical indicators suggest potential short-term volatility, the long-term outlook remains optimistic.  

**8. Recommendation:**

The analysis suggests that TMO is a solid long-term investment, particularly for investors seeking exposure to the healthcare and scientific instrument sectors.  The company's robust fundamentals and potential for continued growth support this outlook. However, the current oversold conditions and short-term price pressure might warrant caution for short-term traders. It's recommended to closely monitor market trends and fundamental developments for optimal trading decisions. 
